Greylin Investment Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $3.73M | Sell |
54,344
-10,024
| -16% | -$669K | 0.62% | 31 |
|
|
2024
Q1 | $4.71M | Sell |
64,368
-32,265
| -33% | -$2.48M | 0.76% | 26 |
|
|
2023
Q4 | $7.83M | Sell |
96,633
-23,560
| -20% | -$1.83M | 1.35% | 13 |
|
|
2023
Q3 | $9.01M | Sell |
120,193
-21,862
| -15% | -$1.68M | 1.62% | 11 |
|
|
2023
Q2 | $10.9M | Sell |
142,055
-22,464
| -14% | -$1.79M | 1.98% | 8 |
|
|
2023
Q1 | $13.7M | Sell |
164,519
-6,925
| -4% | -$574K | 2.49% | 6 |
|
|
2022
Q4 | $14.7M | Sell |
171,444
-18,290
| -10% | -$1.45M | 2.71% | 7 |
|
|
2022
Q3 | $11.7M | Sell |
189,734
-63,422
| -25% | -$4M | 2.43% | 10 |
|
|
2022
Q2 | $15.6M | Buy |
253,156
+24,586
| +11% | +$1.52M | 3.02% | 8 |
|
|
2022
Q1 | $13.6M | Buy |
228,570
+41,130
| +22% | +$2.63M | 2.33% | 8 |
|
|
2021
Q4 | $13.6M | Sell |
187,440
-300
| -0.2% | -$20.7K | 2.57% | 7 |
|
|
2021
Q3 | $13.1M | Buy |
187,740
+1,630
| +0.9% | +$115K | 2.69% | 7 |
|
|
2021
Q2 | $12.8M | Buy |
186,110
+84,629
| +83% | +$5.65M | 2.48% | 8 |
|
|
2021
Q1 | $6.56M | Buy |
101,481
+4,512
| +5% | +$291K | 1.37% | 14 |
|
|
2020
Q4 | $5.65M | Buy |
96,969
+10,103
| +12% | +$610K | 1.32% | 15 |
|
|
2020
Q3 | $5.49M | Buy |
86,866
+78,204
| +903% | +$5.42M | 1.46% | 14 |
|
|
2020
Q2 | $666K | Sell |
8,662
-760
| -8% | -$58.2K | 0.19% | 43 |
|
|
2020
Q1 | $704K | Sell |
9,422
-5,565
| -37% | -$385K | 0.22% | 39 |
|
|
2019
Q4 | $974K | Buy |
14,987
+280
| +2% | +$18.2K | 0.22% | 43 |
|
|
2019
Q3 | $932K | Sell |
14,707
-340
| -2% | -$22.2K | 0.22% | 42 |
|
|
2019
Q2 | $1.02M | Buy |
15,047
+3,600
| +31% | +$237K | 0.23% | 42 |
|
|
2019
Q1 | $744K | Buy |
11,447
+5
| +0% | +$332 | 0.17% | 52 |
|
|
2018
Q4 | $716K | Sell |
11,442
-131,460
| -92% | -$9.19M | 0.17% | 49 |
|
|
2018
Q3 | $11M | Sell |
142,902
-1,185
| -0.8% | -$89.5K | 2.38% | 8 |
|
|
2018
Q2 | $10.2M | Buy |
144,087
+64,920
| +82% | +$4.58M | 2.21% | 12 |
|
|
2018
Q1 | $5.97M | Buy |
79,167
+30,330
| +62% | +$2.41M | 1.29% | 15 |
|
|
2017
Q4 | $3.5M | Buy |
48,837
+23,060
| +89% | +$1.75M | 0.76% | 20 |
|
|
2017
Q3 | $2.09M | Sell |
25,777
-670
| -3% | -$51.2K | 0.48% | 29 |
|
|
2017
Q2 | $1.87M | Buy |
26,447
+8,395
| +47% | +$559K | 0.43% | 30 |
|
|
2017
Q1 | $1.23M | Buy |
+18,052
| New | +$1.27M | 0.28% | 35 |
|
|
2016
Q4 | – | Sell |
-4,470
| Closed | -$354K | – | 69 |
|
|
2016
Q3 | $354K | Buy |
4,470
+1,700
| +61% | +$138K | 0.09% | 60 |
|
|
2016
Q2 | $231K | Buy |
+2,770
| New | +$246K | 0.06% | 66 |
|
Other funds holding GILD
Greylin Investment Management's GILD Position: Q2 2024 in Review
Greylin Investment Management reduced its Gilead Sciences (GILD) stake by 16% in Q2 2024, selling an estimated $669K and leaving 54,344 shares worth $3.73M. The position accounts for 0.62% of the portfolio, ranked #31.
Greylin Investment Management first reported a position in GILD in Q2 2016 and has held it in 32 quarters since. The position peaked at $15.6M in Q2 2022. 1,679 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Greylin Investment Management held 54,344 shares of Gilead Sciences worth $3.73M as of Q2 2024.
- Greylin Investment Management sold 10,024 Gilead Sciences shares in Q2 2024, an estimated $669K.
- Gilead Sciences made up 0.62% of Greylin Investment Management's portfolio in Q2 2024, its #31 holding.
- Greylin Investment Management first reported a position in Gilead Sciences in Q2 2016 and has held it in 32 quarters since.
- Greylin Investment Management's Gilead Sciences position peaked at $15.6M in Q2 2022.
- 1,679 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Greylin Investment Management's 13F filing for Q2 2024, filed 19 Jul 2024.